Cargando…

Raltegravir switch improves hepatitis C transaminitis in HIV-1 and hepatitis C (HCV) co-infected individuals

Detalles Bibliográficos
Autores principales:	Cevik, Muge, Singh, Gurmit, Dickinson, Laura, Scourfield, Andrew, Boffito, Marta, Nelson, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360349/ http://dx.doi.org/10.1186/1742-4690-9-S1-O7

Ejemplares similares

Co-infection with hepatitis C virus (HCV) in Estonian intravenous drug users HIV epidemic
por: Huik, Kristi, et al.
Publicado: (2014)

The pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers
por: Ashby, J, et al.
Publicado: (2010)

Hepatitis C new drugs
por: Wedemeyer, H
Publicado: (2010)

When Does Transaminitis Become Acute Hepatic Failure? What Is the Management of Transaminitis and Acute Hepatic Failure?
por: Hieger, Michelle A.
Publicado: (2018)

Impact of Raltegravir on immune reconstitution and thymopoiesis in HIV-1-infected patients with undetectable viremia
por: Garrido, C, et al.
Publicado: (2010)

Hepatitis C — feedback from the Consensus Conference on the Management of Acute Hepatitis C (AHC) in Paris, May 2010
por: Vogel, M
Publicado: (2010)

Low prevalence of hepatitis C infection among HIV-infected individuals in Slovenia: a nationwide study, 1985–2013
por: Seme, Katja, et al.
Publicado: (2014)

Efficacy and safety of peginterferon alfa-2a + RBV in cHCV/HIV- vs cHCV-infected patients: interim analysis of a multicenter German cohort
por: Baumgarten, A, et al.
Publicado: (2010)

Inflammatory patterns in patients with chronic hepatitis C
por: Ion, Daniela Adriana, et al.
Publicado: (2013)

Hepatitis C virus (HCV) infection and re-infection among HCV- and HIV/HCV-infected injection drug users
por: Conway, B, et al.
Publicado: (2010)

High levels of polymorphisms related to raltegravir resistance among raltegravir-naïve individuals in Brazil
por: Pena, N Mantovani, et al.
Publicado: (2010)

Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961)
por: Eron, J, et al.
Publicado: (2010)

Safety and efficacy of ombitasvir – 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens
por: Eron, Joseph J, et al.
Publicado: (2014)

Influence of liver fibrosis stage on nevirapine plasma concentration in HIV-infected patients with chronic hepatitis C virus
por: Dragovic, Gordana, et al.
Publicado: (2014)

Hepatic cytolysis and Hepatitis E Virus infection in HIV-positive patients
por: Mazeron, Marie-Christine, et al.
Publicado: (2010)

Hepatitis C (HCV) therapy for HCV mono-infected and HIV-HCV co-infected individuals living in Nepal
por: KC, Sudhamshu, et al.
Publicado: (2020)

Hepatitis C diagnosics: clinical evaluation of the HCV-core antigen determination
por: van Helden, Josef
Publicado: (2014)

Metabolic risk factors for liver inflammation in a cohort of chronic hepatitis C patients
por: Rădulescu, Mihaela Andreea, et al.
Publicado: (2014)

Hepatitis C virus fails to activate NF-kappaB signaling in plasmacytoid dendritic cells
por: Stranska, Ruzena, et al.
Publicado: (2012)

Switching to a 'nuke-sparing' raltegravir/atazanavir combination: an individualised approach
por: Grant, A, et al.
Publicado: (2010)

HTLV-1 infection modulates the immune response in HIV-HCV coinfected patients and may increase spontaneous HCV clearance
por: Bahia, Fabianna, et al.
Publicado: (2014)

Hepatitis C Virus (HCV) Infection and Hepatic Steatosis
por: Yoon, Eugene J., et al.
Publicado: (2006)

Hepatic lesions
por: Schima, Wolfgang, et al.
Publicado: (2015)

The MONET trial: correlation between Hepatitis C coinfection and HIV RNA responses during darunavir/ritonavir monotherapy, for patients with HIV RNA <50 copies/mL at baseline
por: Arribas, Jose R, et al.
Publicado: (2010)

P231 HEPATITIS C VIRUS POTENTLY ACTIVATES HUMAN CD161/MAIT (MUCOSAL ASSOCIATED INVARIANT T) CELLS
por: Thompson, F.M., et al.
Publicado: (2014)

A11 NEXT STEPS IN MICRO-ELIMINATION: PEER POINT OF CARE HEPATITIS C TESTING IN VICTORIA, BRITISH COLUMBIA
por: Barnett, T, et al.
Publicado: (2023)

Development of a test system for simultaneous detection of HIV RNA and Hepatitis C virus (HCV) and DNA of Hepatitis B virus (HBV) in blood samples
por: Shahrokhi, Nader, et al.
Publicado: (2010)

Screening of differentially expressed gene in HIV/HCV co-infected patients
por: Yang, zhengrong, et al.
Publicado: (2010)

Liver fibrosis is strongly associated with an enhanced level of immunosuppressive tryptophan catabolism independently of HCV viremia in ART-treated HIV/HCV co-infected patients
por: Jenabian, Mohammad-Ali, et al.
Publicado: (2014)

Raltegravir, tenofovir, and emtricitabine in an HIV-Infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver toxicity
por: Ortu, F, et al.
Publicado: (2010)

Long-term protection of hepatitis B vaccine in HIV-infected patients
por: Biekre, R, et al.
Publicado: (2014)

Hepatitis C treatment initiation in HIV-HCV coinfected patients
por: Cotte, Laurent, et al.
Publicado: (2016)

Epidemiology of Hepatitis C Virus (HCV) Infection
por: Sy, Theodore, et al.
Publicado: (2006)

Seroprevalence of hepatitis B, hepatitis C and HIV in ICU patients
por: Bayir, H, et al.
Publicado: (2015)

Metabolic features in chronic HCV infected patients
por: Rădulescu, Mihaela Andreea, et al.
Publicado: (2013)

Response to treatment of hepatitis C in HCV/HIV co-infected patients is not influenced by either abacavir or tenofovir with weight-based ribavirin
por: Bhatti, L, et al.
Publicado: (2010)

Efficacy and safety of hepatitis C direct-acting protease inhibitors (DAA-PI ) in real life in HIV-HCV coinfected patients
por: Ménard, A, et al.
Publicado: (2014)

Carcinovic cohort: prognostic factors of death in HIV/HCV coinfected patients with hepatocellular carcinoma (HCC)
por: Gelu-Simeon, M, et al.
Publicado: (2014)

Host genetics of HCV disease — IL28B
por: Fellay, J
Publicado: (2010)

Neurocognitive impairment screening in Romanian HCV infected patients
por: Cercel, Ioana-Catrinel, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_2efrf59cr3bcqeh6m1gcefbkgh